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Abstract
Background: To elucidate the mechanism by which local delivery of 3-morpholino-sydnonimine (SIN-1) affects
intimal hyperplasia after percutaneous transluminal coronary angioplasty (PTCA).
Methods: Porcine coronary arteries were treated with PTCA and immediately afterwards locally treated for 5
minutes, with a selective cytosolic guanylate cyclase inhibitor, 1 H-(1,2,4)oxadiazole(4,3-alpha)quinoxaline-1-one
(ODQ) + SIN-1 or only SIN-1 using a drug delivery-balloon. Arteries were angiographically depicted,
morphologically evaluated and analyzed after one and eight weeks for actin, myosin and intermediate filaments
(IF) and nitric oxide synthase (NOS) contents.
Results: Luminal diameter after PCI in arteries treated with SIN-1 alone and corrected for age-growth was
significantly larger as compared to ODQ + SIN-1 or to controls (p < 0.01). IF/actin ratio after one week in SIN-1
treated segments was not different compared to untreated segments, but was significantly reduced compared to
ODQ + SIN-1 treated vessels (p < 0.05). Expression of endothelial NADPH diaphorase activity was significantly lower
in untreated segments and in SIN-1 treated segments compared to controls and SIN-1 + ODQ treated arteries (p <
0.01). Restenosis index (p < 0.01) and intimal hyperplasia (p < 0.01) were significantly reduced while the residual
lumen was increased (p < 0.01) in SIN-1 segments compared to controls and ODQ + SIN-1 treated vessels.
Conclusions: After PTCA local delivery of high concentrations of the NO donor SIN-1 for 5 minutes inhibited injury
induced neointimal hyperplasia. This favorable effect was abolished by inhibition of guanylyl cyclase indicating
mediation of a cyclic guanosine 3’,5’-monophosphate (cGMP)-dependent pathway. The momentary events at the
time of injury play crucial role in the ensuring development of intimal hyperplasia.
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Background
Endothelial injury after PTCA results in denudation or
even rupture of the internal elastic lamina, causing
damage to smooth muscle cells (SMC) and release of
signal substances, which in turn contribute to neointi-
mal formation and often restenosis [1].
Endothelial-derived NO reduces these events and
modulates several physiological processes in the vascula-
ture, including vascular tone, SMC migration, leukocyte
adhesion, platelet adhesion and aggregation [2]. The
biologic response of SMC and endothelial cells to NO
differs. NO inhibits SMC proliferation and can increase
apoptotic SMC cell death [3]. On the contrary NO in
physiological concentrations enhances endothelial prolif-
eration and reduces endothelial cell apoptosis [4-7]. NO
exerts its effects both by a cGMP-dependent and a
cGMP-independent pathway [8].
Orally or intravenously administered NO precursors
and donors have been shown to moderately affect inti-
mal hyperplasia after arterial injury in animal and
human studies [9-12]. These studies have been ham-
pered by the fast degradation rate of NO in blood,
which allows only minimal amounts of NO, if any, to
reach the injured area. However, intrapericardial delivery
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nosis [13]. The NO donor SIN-1 has recently been
shown to reduce intimal hyperplasia after PTCA, and
may be advantageous as it releases NO by fast and
spontaneous degradation[14].
The aim of the present study was to evaluate the
effect of locally delivered NOo ni n t i m a lh y p e r p l a s i a
after PTCA, and to investigate whether the NO donor
SIN-1 affects intimal hyperplasia via a cGMP dependent
pathway.
Methods
Animal care and handing followed guidelines in the
National Institutes of Health (NIH publication No 85-
23, revised 1996). The local ethical committee for ani-
mal care approved the study. Twenty-nine domestic pigs
weighing 21.5 ± 0.6 kg were premedicated with azaper-
one 2 mg/kg intramuscularly 30 minutes before the pro-
cedure. After induction of anesthesia with thiopental 5-
25 mg/kg the animals were orally intubated with cuffed
endotracheal tubes. A slow infusion of 1.25 μl/mL Fen-
tanyl in Ringer-acetate was started at a rate of 1.5 mL/
min and adjusted as needed. Mechanical ventilation was
then established with a Siemens-Elema 300 B ventilator
with a mixture of nitrous oxide (70%) and oxygen (30%).
Hypnosis was complemented with small intermittent
doses of 5 mg meprobamat as needed.
An 8 F introducer sheath (Cordis, USA) was inserted
into the left carotid artery and 10,000 IU Heparin given.
After an angiogram, PTCA was performed in the left
anterior descending artery (LAD) and in the left circum-
flex artery (LCX). The artery was dilated at 8 atm with a
20 × 3.0 or 3.5 mm dilation balloon (Boston Scientific,
USA) using balloon: artery ratios 1.3:1. Before each bal-
loon inflation the pig was given intra-cardially 100 μg
nitro-glycerine to avoid spasm and to obtain consistent
epicardial artery dilation. Inflation time was 30 s, and
immediately after deflation a corresponding 3 or 3.5 ×
20 mm drug delivery catheter (Dispatch, Boston Scienti-
fic, USA) was inserted into the PTCA-treated site and
inflated at 8 - 10 atm. Effort was taken to minimize the
time from balloon angioplasty to the time of drug treat-
ment (approximately 1 minute), in order to avoid
thrombus formation. Infusion with 10
-5 MO D Q ,a
selective inhibitor of NO-sensitive guanylyl cyclase activ-
ity (Tocris Cookson, UK.) was performed at a rate of 1
ml/min. for 5 minutes. The Dispatch balloon was
flushed with 1 ml saline and continued with infusion of
5m l1 0
-4 M SIN-1 for 5 minutes. The selected high
dose has been used in earlier studies, and we have
recently demonstrated an inhibiting effect on intimal
hyperplasia after 10 minutes [15-17]. A 0.5-mm over-
dilation was performed for 30 seconds in the corre-
sponding, still untreated LAD or LCX, which were
thereafter treated only with SIN-1. In five animals
arteries used as controls, underwent PTCA and were
treated with NaCl 1 ml/min for 10 minutes. Treatment
of the arteries was randomized.
During coronary artery occlusion perfusion pressure
was increased by a dopamine infusion and small doses
of noradrenaline (10 μ g). Xylocain, 10 mg/kg was
injected i.v. before releasing the occlusion to prevent the
occurrence of malignant arrhythmias during reperfusion.
The catheters were withdrawn after a final angiogram.
The left carotid artery was surgically reconstructed, and
the skin sutured. Postoperatively, the pigs received 0.15
mg buprenorphine and 5 ml Streptocillin Vet. The pigs
were given 250 mg aspirin daily starting at the day of
the procedure.
One week after the angioplasty, one group of eleven
pigs was sedated and euthanized with an intra-cardiac
injection of 40-mmol potassium chloride. The treated
segments were harvested immediately, using micro-sur-
gical technique and cut into a proximal, a medial and a
distal segment. An untreated segment was also obtained
distal to the treated area. The vessel segments were ana-
lyzed electrophoretically for the following proteins actin,
myosin and intermediate filaments (IF) and histochemi-
cally for NADPH diaphorase in order to visualize the
presence of NOS.
Eight weeks postoperatively a second group of sixteen
pigs was euthanized as described above. Coronary angio-
grams were performed and the arteries perfusion-fixated
at 100 mmHg with 4% formaldehyde before harvesting.
T h ea r t e r i e sw e r ee x a m i n e db yr o u t i n eh i s t o l o g ya n d
NADPH histochemistry. A perfusion-fixated vessel seg-
ment distal to each of the treated areas was harvested as
well.
Angiographic examination
Fluoroscopic video recordings and angiographic stills
were examined. Using the guide catheter as reference,
luminal diameter was calculated before, immediately
after treatment, and at 8 weeks. Pigs grow fast in 8
weeks, in order to determine the growth of the artery;
the diameter of the proximal reference segment,
approximately 1 cm proximal to the treated area, was
measured at the time of treatment and after 8 weeks.
Artery growth was thus calculated as the difference in
diameter of the arterial reference segments.
The absolute diameter of the treated segments at 8
weeks was reduced by age growth, in order to measure
the angiographic late loss without the influence of nat-
ural growth in this non-stent model.
Electrophoretic examination
To investigate the relative content of actin, myosin and
intermediate filament protein (IF) in smooth muscle
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dimensional SDS polyacrylamide gel electrophoresis
(SDS-PAGE). The vascular preparations were homoge-
nized in an SDS-buffer (composition: 25 mM tris
(hydroxymethyl) aminomethane HCl (pH 6.8), 2% SDS,
5% mercaptoethanol and 10% glycerol) at a concentra-
tion of 50 μl/mg tissue wet weight. The homogenate
was then boiled for 2 minutes and centrifuged at 10,000
rpm for 5 minutes. The supernatant was removed and
stored at -20°C before electrophoretic analysis. The
SDS-PAGE was performed essentially as described by
Malmqvist et al. [18] using 8% polyacrylamide gels in a
BioRad minigel system. The gels were stained with Coo-
massie blue, destained and scanned using a GS-300 den-
sitometer (Hoeffer Scientific Instruments, USA). The
areas under the myosin heavy chains, actin and inter-
mediate filament bands were evaluated. The ratios of
actin/myosin and intermediate filaments/actin were cal-
culated from these areas.
NADPH histochemistry
The vascular segments were fixed overnight in a mixture
of 2% formaldehyde and 0.2% picric acid in phosphate
buffer (pH 7.2) or in buffered 4% formaldehyde, fol-
lowed by rinsing in Tyrode’s solution containing 10%
sucrose. Specimens were frozen on dry ice and cut in a
cryostat at a thickness of 10 μm. NADPH diaphorase
activity was rendered visible by incubation of the sec-
tions for 45 minutes in 0.1 M Tris-HCl (pH 7.2) con-
taining 1 mM NADPH (Sigma, USA), 0.2% Triton X-
100 at 37°, followed by washing in Tris-HCl [19].
Each segment was cut into multiple sections, exam-
ined under a light microscope and photographed with
maximum of light, creating a completely yellow photo-
graph where only NADPH cells stained dark blue. The
images obtained were transferred to a CD-ROM in
Kodak format and imported into Photoshop 5.5 (Adobe
Inc., USA). These photographs were subtracted into a
black and white image. Due to the gray scale practically
only the NADPH-stained endothelial cells were black. A
45 × 15 mm representative portion of the cross sectional
screen-area consisting of endothelium and media was
selected. From the histogram menu, the percentage of
black pixels in the photo was registered as percentage of
the total number of pixels in the selection.
Histo-morphological examination
Each sample was cut further into 4-14 sections, which
were stained with haematoxylin-eosin for routine histo-
logical evaluation. A similar number of sections was cut
and stained with van Gieson elastica and used for mor-
phological measurements. Measurements were per-
formed without knowledge of the treatment of the
segments.
The intimal (I), medial (M), and luminal (L) areas as
well as the internal elastic lamina (IEL) circumference
and the IEL fracture length (F) were measured using
computerized digital planimetry with a video microscope
(Olympus BX 50 F4, Japan) and customized software
(Analysis 3.0, Soft Imaging System, Germany). Vessel
size was assessed by measuring the area circumscribed
by the outer border of the external elastic lamina (EEL
area). Injury index = F/IEL, was calculated as fracture
length of the IEL normalized for the size of the artery
by the circumference of the IEL. Intimal hyperplasia was
also normalized for the total artery wall area: I/(I+M).
The restenosis index = ((I/(I+M))/(F/IEL) could then be
calculated taking into account the degree of injury.
Changes in vessel geometry after injury and repair
denoted the residual lumen and were defined as L/(L+I)
[20,21].
Summary of the study design
A total of 29 pigs were treated with local drug delivery
in the LAD as well as the LCX with either SIN-1 alone
or ODQ + SIN-1, except for the control pigs were only
NaCl was used. After 7 days 11 pigs were sacrificed and
the treated segments examined by electrophoresis and
NADPH histochemistry. 56 days later the rest were
sacrificed, 5 control animals and 11 pigs were examined
by NADPH, angiography, electrophoresis, histochemis-
try, and histo-morphology
Statistics
One-way ANOVA with Bonferroni post hoc test was
used to compare multiple means. Mann-Whitney test
was used for comparison between two groups. p values
< 0.05 were considered significant. Data are presented
as mean ± SD.
Results
Two pigs, which were excluded from the study, died
peri-procedurally due to ischemic events. The remaining
pigs survived the procedure without complications. The
pigs weighed at baseline 21.5 ± 0.64; after 7 days 23.1 ±
1.28 and increased to 41.5 ± 2.14 Kg at 56 days. Blood
pressure was stable throughout the drug delivery
procedure.
Angiographic examination
The diameters of the proximal reference segments, used
for calculating age growth, were 3.24 ± 0.40 mm at day
0 and 3.73 ± 0.44 mm at 8 weeks resulting in 0.55 ±
0.31 mm diameter growths (17%). There was no signifi-
cant difference in growth between treatment groups.
The angiographic results are presented in (Table 1).
With or without age correction SIN-1 treated arteries
had significantly larger diameter compared to control (p
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meter was not changed significantly compared to
control.
Late loss occurring in treated segments after 8 weeks
was calculated as the artery diameter after PTCA at day
0 minus the diameter at 8 weeks adjusted for growth.
Electrophoretic examination
Biochemical analysis of the effect of SIN-1 on inter-
mediate filament proteins one week after treatment is
presented in (Figure 1). The ratio of IF/actin in SIN-1
treated segments did not differ significantly from the
corresponding ratios in untreated segments. PTCA fol-
lowed by ODQ prior to SIN-1 treatment caused a sig-
nificant increase in the IF/actin ratio compared to
untreated arteries as well as SIN-1 treated vessels. IF/
myosin ratio was not affected by SIN-1 whereas PTCA
followed by ODQ+ SIN-1 treatment non-significantly
i n c r e a s e dt h er a t i o( p=0 . 0 6 )( F i g u r e2 ) .W ec o u l dn o t
detect any statistically significant changes in the rela-
tive amount of myosin heavy chain normalized to
actin.
NADPH histochemistry
At 8 weeks saline treated controls showed significant
increase in NADPH staining compared to untreated ves-
s e l s( p<0 . 0 1 )a san o r m a lr e s p o n s et oa r t e r yi n j u r y .
The increase was inhibited after PTCA with SIN-1treat-
ment, whereas PTCA with ODQ prior to SIN-1 treat-
ment resulted in significant elevation of NADPH
staining (p < 0.01) (Figure 3).
The increase in NADPH staining after ODQ + SIN-1
application was detectable one week after treatment
(Figure 4).
Changes in NADPH diaphorase activity were circum-
scribed to treated segments while there were no changes
observed in correlating matched distal untreated
segments.
Histo-morphological examination
8 weeks after treatment all arteries were patent. There
were no statistically significant differences in the inter-
nal elastic lamina fracture lengths inflicted to the
arteries. In the SIN-1 treated segments, the restenosis
index (0.60 ± 0.65) was 72% less and the amount of inti-
mal hyperplasia (0.07 ± 0.06) 71% reduced compared to
controls. The residual lumen (0.92 ± 0.08) was 26%
Table 1 Angiographic characteristics
Diameter
measurements
ODQ+
SIN-1
mm
n=1 1
SIN-1
mm
n=1 1
NaCl
Control
mm
n=5
P
-value
Pre- treatment (A) 2.62 ± 0.36 2.76 ± 0.35 2.81 ± 0.41 ns
After treatment (B) 2.77 ± 0.38 2.93 ± 0.34 3.10 ± 0.37 ns
After 8 weeks (C) 3.17 ± 0.35 3.53 ± 0.30 3.07 ± 0.25 < 0.01
Age-corrected at 8
weeks (D)
2.60 ± 0.32 3.12 ± 0.41 2.62 ± 0.29 < 0.01
Late Loss (B-D) 0.21 ± 0,30 -0.19 ± 0,51 0.48 ± 0,31 < 0,05
Legend to table 1: Age related growth of the arteries was similar for segments
treated either with SIN-1 or ODQ + SIN-1 or to controls. With or without age
correction, SIN-1 treated arteries had after 8 weeks significantly larger
diameter compared to ODQ + SIN-1 or control segments. Data presented as
mean ± SD. One way ANOVA test.
Figure 1 Artery wall ratio of intermediate filaments/actin after
PTCA with ODQ prior to SIN-1 treatment or SIN-1 alone.
Legend: Figure 1 depicts the ratio of intermediate filaments to
actin in treated and untreated segments. ODQ + SIN-1 caused a
significant increase in the ratio compared to untreated segments
and segments treated only with SIN-1 (p < 0.05). All groups
summarize data from six animals. Data presented as mean ± SD.
Mann-Whitney test.
Figure 2 Artery wall ratio of intermediate filaments/myosin
after PTCA with ODQ prior to SIN-1 treatment or SIN-1 alone.
Legend: Figure 2 depicts the ratio of intermediate filaments to
myosin in treated and untreated segments. ODQ + SIN-1 caused a
non-significant increase in the ratio compared to untreated
segments and segments treated only with SIN-1 (p = 0.06). All
groups summarize data from six animals. Data presented as mean ±
SD. Mann-Whitney test.
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in EEL compared to controls. Intimal hyperplasia is sig-
nificantly decreased after SIN-1 treatment compared to
controls (p < 0.01). Addition of ODQ prior to SIN-1
treatment resulted in response to injury similar to the
response of controls (NaCl) (Table 2).
Discussion
This study shows that delivery of the NO donor SIN-1
at the site of a PTCA injury for 5 minutes decreases sig-
nificantly intimal hyperplasia/restenosis. Inhibition of
guanylyl cyclase by ODQ attenuated the beneficial effect
of NO delivery indicating the involvement of a cGMP
dependent pathway. In this experiment additional ODQ
to the delivery system did not increase intimal hyperpla-
sia compared with controls.
Application of a NO donor was chosen in the present
study, since NO interferes with the restenotic process at
several levels. NO has three major properties in the vas-
cular system: anti-ischemic/anti-hypertensive, anti-ather-
osclerotic and anti-thrombotic. Nitric oxide interferes
with most intracellular messengers because it diffuses
rapidly and isotopically through tissues [2].
The action of NO in regulating growth and migration
of vascular smooth muscle cells is mainly mediated
through a cGMP-dependent mechanism [22,23]. Acti-
vated platelets participate by adhering to endothelial
ulcerations and releasing mitogens and cytokines, which
induce SMC migration and proliferation. SMCs in the
vascular lesion change their phenotype from contractile
to secretory [8]. In the present study we examined
whether the beneficial effect of an externally applied
NO donor in a high concentration could be modified by
a guanylyl cyclase inhibitor,a sa ni n d i c a t i o nf o rt h e
implication of a cGMP dependent pathway in the devel-
opment of intimal hyperplasia/restenosis.
NO, derived from endothelial cells, modulates SMC
migration and reduces production of extracellular
matrix [24,25]. In physiological concentrations NO con-
tributes to human endothelial cell survival, whereas in
high concentrations NO induces endothelial cell apopto-
sis [26,27]. SIN-1 spontaneously releases NO, which can
further react with superoxide and at high concentrations
form peroxynitrite (ONOO
-) [28]. NO scavenges super-
oxide anion directly and independent of cGMP. Peroxy-
nitrite is a selective oxidant [29] causing nitration of
structural proteins [28]. SIN-1 in concentrations of 400
Figure 3 NADPH stained pixels 8 weeks after PTCA treated
with ODQ prior to SIN-1 or SIN-1 alone. Legend to figure 3:
NADPH staining at 8 weeks was significantly deceased in SIN-1
treated arteries compared to controls (p < 0.01). There was no
significant difference between SIN-1 treated and untreated
segments. NADPH staining in control segments and ODQ + SIN-1
treated segments was increased compared to untreated arteries.
There was no difference in NADPH staining between controls and
ODQ + SIN-1 treated vessels. All groups summarize data from six
animals. Data presented as mean ± SD. * indicates p < 0.05 One-
way ANOVA with Bonferroni post hoc test.
Figure 4 NADPH stained pixels 1 week after PTCA treated with
ODQ prior to SIN-1 or SIN-1 alone. Legend to figure 4: At one
week there was no significant difference in NADPH staining
between the SIN-1 treated arteries compared to untreated vessels.
NADPH staining was significantly higher in ODQ + SIN-1 treated
segments compared to SIN-1 treated as well as untreated vessels (p
< 0.01). All groups summarize data from six animals. Data presented
as mean ± SD. * indicates p < 0.05 Mann-Whitney test.
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due to peroxynitrite. However, concentrations of 200
μM SIN-1 caused cellular apoptosis [30]. In the present
study it is plausible that production of peroxynitrite at a
concentration of 100 μM SIN-1, affected our results.
However, since the effect of SIN-1 on intimal hyperpla-
sia was inhibited in the presence of ODQ, a cytosolic
guanylyl cyclase inhibitor, this assumption seems
unlikely.
PTCA treatment causes intimal hyperplasia [20]. In the
present study we have shown angiographically increased
artery diameter after local delivery of SIN-1. A clinical
multicenter study (ACCORD) indentified modest
improvement of restenosis after intravenous or oral
administration of sydnonimines [11]. Yet, a recent rando-
mized trial of 166 patients failed to show benefit of 8 mg/
day controlled release tablets for 6 month on restenosis
after PTCA [12]. Site-specific delivery of SIN-1 affects
more potently intimal thickening as in this case the bio-
logical action of NO is not circumscribed by immediate
degradation upon exposure oxyhaemoglobin. Exposure of
vascular tissue to NO delivery for a very short interval (5
minutes) has been proven in this and a previous study to
exert long-lasting effects on tissue remodelling and
patency [14]. These effects are of outmost clinical rele-
vance in everyday treatment of arthrosclerosis.
Biochemical analysis of the arterial wall proteins actin,
myosin and intermediate filaments was performed one
week postoperatively, as histological examination is
uncertain at this time point. The SMC cytoskeleton con-
tains a high amount of IF but IF can be found in all
types of cells. The function of IF in SMC is not estab-
lished, but IF is increased in hypertrophy and hyperpla-
sia [31]. The content of actin is not changed in smooth
muscle in intimal hyperplasia when related to total tis-
sue weight [32]. Since SMC adaption is associated with
an increase in IF while the amount of actin is
unchanged, we chose to use the IF/actin ratio as a mea-
surement of PTCA induced adaption to arterial injury.
We found that SIN-1 treatment after PTCA affects the
structural IF system in the SMC in a pronounced way.
NO released by SIN-1 and applied to the injured area
inhibits the increase of the IF/actin and IF/myosin
ratios. On the contrary when the cGMP dependent NO-
pathway is blocked by ODQ, IF/actin increase signifi-
cantly, indicating a rapid turnover of IF proteins and
cell growth after injury.
It cannot be excluded that the increased IF/actin and
IF/myosin ratios seen after ODQ+SIN-1 treatment repre-
sents an increase in the number of non-SMC, activated
at the time of injury. The present results suggest a possi-
ble role for NO in SMC remodeling in response to injury,
as exposure to SIN-1 significantly reduced the IF/actin
ratio, which directly correlated to the degree of neointi-
mal formation at 8 weeks. Interestingly, a recent study
has demonstrated that hematopoietic stem cells give rise
to SMC after angioplasty [33]. If this is the case our
results indicate that NO may influence stem cells.
In the heart, nitric oxide synthase (NOS) is found
almost exclusively in vessels [30]. Practically none is
found in the endocardium, valves or cardiac muscle
fibers. Most NOS in the heart is in the form of the
endothelial isoform (eNOS). Recently, it has been sug-
gested that eNOS localized in the endothelial caveolae
may act as a mechanosensor to couple NO release to
long time hemodynamic changes that regulate extracel-
lular matrix turnover, endothelial and SMC prolifera-
tion, migration and responsiveness to growth factors;
events ultimately responsible for artery remodeling
[8,24,25]. The inducible isoform (iNOS) is only found
after injury [34]. In an attempt to establish the amount
of NOS in the endothelium after PTCA treatment with
SIN-1 or ODQ+SIN-1, NADPH diaphorase histochemis-
try of the arteries was performed. This histochemical
reaction is sensitive to temperature and fixation-time.
For this reason treated segments were always matched
and compared with their distal untreated segment,
which was harvested simultaneously. Although NADPH
also marks other enzymes such as cytochrome
P450 reductase, NADPH oxidase and non-specific
Table 2 Histo-pathological characteristics of PTCA injured
coronary arteries 8 weeks after treatment with ODQ +
SIN-1 and SIN-1 and control
8 weeks after
treatment
ODQ+
SIN-1
n=1 1
SIN-1
n=1 1
NaCl
Controls
n=5
P
-value
EEL area (mm
2) 2.79 ± 0.55 2.64 ± 1.11 3.28 ± 1,16 ns
Medial area(M) (mm
2) 1.16 ± 0.36 1.27 ± 0.46 1.27 ± 0.47 ns
Intimal area (I) (mm
2) 0.50 ± 0.59 0.11 ± 0.10 0.73 ± 0.69 < 0.01
Luminal area (L)
(mm
2)
1.12 ± 0.36 1.26 ± 0.67 1.28 ± 0.91 ns
IEL length (mm) 3.91 ± 1.06 4.40 ± 0.73 4.20 ± 1.37 ns
Fracture length (F)
(mm)
0.71 ± 0.54 0.91 ± 0.73 1.21 ± 0.77 ns
Injury index
1 0.22 ± 0.21 0.21 ± 0.19 0.35 ± 0.29 ns
Residual lumen
2 0.73 ± 0.26 0.92 ± 0.08 0.63 ± 0.30 < 0.01
Restenosis index
3 2.10 ± 2.24 0.60 ± 0.65 1.02 ± 0.70 < 0.01
Intimal hyperplasia
4 0.25 ± 0.23 0.07 ± 0.06 0.32 ± 0.24 < 0.01
Results are presented as mean ± SD. One-way ANOVA was used for statistical
evaluation. EEL: External elastic lamina. IEL: Internal elastic lamina.
1Injury index: IEL fracture length/IEL circumference.
2Residual lumen: L/(L+I)
3Restenosis index: (I/I+M)/(F/IEL)
4Intimal hyperplasia: I/(I+M)
Legend to table 2: PTCA followed by SIN-1 treatment demonstrated significant
larger residual lumen and reduced intimal area, restenosis index, and intimal
hyperplasia compared to NaCl treated or if treated with ODQ prior to SIN-1.
Data presented as mean ± SD. One way ANOVA test.
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the liver [35,36]. This response was inhibited by SIN-1.
We attributed this effect to the release of NO as addi-
tion of ODQ abolished the favorable result of SIN-1
application. Events modulating endothelial NOS
appeared early after vascular injury as changes in
NADPH diaphorase staining were present already at one
week. The present findings suggest that NO down-regu-
lates the expression of NOS in newly formed endothelial
cells to normal levels and implicate a long lasting
change in the mRNA expression of endothelial cells
[37]. A plausible alternative explanation may be that the
local delivery of SIN-1, leads to a greater degree of local
endothelial loss, which is not recovered at later time-
points as compared with NaCl treated animals. How-
ever, in this case one would expect decreased NADPH
activity whenever SIN-1 is applied even in the presence
of ODQ. Our results do not show decrease when ODQ
is used, indicating that the SIN-1 effect is mediated
through the cGMP dependent NO pathway, which
requires functioning endothelium.
Porcine coronary arteries respond to injury with con-
strictive remodeling, elastic recoil and tissue prolifera-
tion, in a manner similar to human arteries [38,39].
Development of intimal hyperplasia is related to the
degree of injury [20] and events at the onset [14]. There
was no significant difference in the IEL fracture length
inflicted to the arteries, but the arteries treated with
SIN-1 had a 72% lower restenosis index, 71% less inti-
mal hyperplasia compared to controls, and 26% larger
residual lumen. This effect is apparently due to NO
since it is abolished in the presence of ODQ.
Conclusions
Events at the onset of injury are crucial to the process of
neointimal formation. Intimal hyperplasia/restenosis is
significantly reduced by application of SIN-1 immedi-
ately after PTCA. The mechanism underlying the effect
of SIN-1 was shown to rely on NO release, which is
inhibited by guanylyl cyclase, both in SMC as well as in
endothelial cells.
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inducible isoform
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